Pulmonary arterial hypertension therapy business Morphogen-IX has been backed by Cambridge Enterprise and Cambridge Innovation Capital in a $23.3m round.
Morphogen-IX, a UK-based developer of pulmonary arterial hypertension treatments based on University of Cambridge research, closed an £18.4m ($23.3m) series B round featuring the Cambridge Enterprise tech transfer office (TTO) yesterday. Cambridge Innovation Capital, the patient capital fund founded by University of Cambridge, also took part in the round, which was led by life sciences-focused…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
